Alnylam Pharmaceuticals - ALNY Stock Forecast, Price & News

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 5 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALNY shares.
View ALNY analyst ratings or view top-rated stocks.

17 Wall Street analysts have issued 12 month price targets for Alnylam Pharmaceuticals' shares. Their ALNY share price forecasts range from $98.00 to $430.00. On average, they expect the company's share price to reach $232.06 in the next twelve months. This suggests a possible upside of 10.8% from the stock's current price.
View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts.

Alnylam Pharmaceuticals' stock was trading at $169.58 at the start of the year. Since then, ALNY stock has increased by 23.5% and is now trading at $209.39.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our ALNY earnings forecast.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its earnings results on Thursday, July, 28th. The biopharmaceutical company reported ($2.29) EPS for the quarter, missing analysts' consensus estimates of ($1.62) by $0.67. The biopharmaceutical company earned $224.80 million during the quarter, compared to the consensus estimate of $256.06 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 204.18% and a negative net margin of 110.91%. Alnylam Pharmaceuticals's revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.61) earnings per share.

Alnylam Pharmaceuticals issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $870.00 million-$930.00 million, compared to the consensus revenue estimate of $1.09 billion.

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALNY stock can currently be purchased for approximately $209.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $25.13 billion and generates $844.29 million in revenue each year. The biopharmaceutical company earns $-852,820,000.00 in net income (profit) each year or ($8.17) on an earnings per share basis.

The company employs 1,665 workers across the globe.

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101.